Charles Schwab
BBNX

Charles Schwab’s Beta Bionics BBNX Stock Holding History

Charles Schwab’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.5M Buy
350,873
+28,406
+9% +$338K ﹤0.01% 2430
2026
Q1 		$3.23M Sell
322,467
-9,156
-3% -$135K ﹤0.01% 2577
2025
Q4 		$10.1M Buy
331,623
+931
+0.3% +$24.9K ﹤0.01% 2138
2025
Q3 		$6.57M Buy
330,692
+228,467
+223% +$4.01M ﹤0.01% 2308
2025
Q2 		$1.49M Buy
102,225
+611
+0.6% +$8.65K ﹤0.01% 2765
2025
Q1 		$1.24M Buy
+101,614
New +$1.89M ﹤0.01% 2769

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Charles Schwab's BBNX Position: Q2 2026 in Review

Charles Schwab increased its Beta Bionics (BBNX) stake by 8.8% in Q2 2026, buying an estimated $338K and bringing the position to 350,873 shares worth $5.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2430.

Charles Schwab first reported a position in BBNX in Q1 2025 and has held it in 6 quarters since. The position peaked at $10.1M in Q4 2025. 133 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • Charles Schwab held 350,873 shares of Beta Bionics worth $5.5M as of Q2 2026.
  • Charles Schwab bought 28,406 Beta Bionics shares in Q2 2026, an estimated $338K.
  • Beta Bionics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2430 holding.
  • Charles Schwab first reported a position in Beta Bionics in Q1 2025 and has held it in 6 quarters since.
  • Charles Schwab's Beta Bionics position peaked at $10.1M in Q4 2025.
  • 133 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.